• SELECT SITE CURRENCY
Select a currency for use throughout the site
Disease and Therapy Review: Overactive Bladder
Timely Data Resources, Inc, November 2012, Pages: 11
Disease and Therapy Reviews were developed to provide a basic understanding of the key facts about a disease and market in a quick, easy-to-read format. These reports are prepared by the senior market research team of Timely Data Resources. Each Disease and Therapy Review provides a concise analysis of the most important information about a particular disease, its treatment, and the market opportunities.
Reports begin with an overview of the condition, and also contain tables that summarize the available worldwide incidence and prevalence data for the condition, a review of current diagnosis strategies and treatment options, general information about the market size, and information about important market trends. The data contained in these reports comes from key industry secondary data sources, such as the Timely Data Resources Incidence and Prevalence Database, and Lange's Current Medical Diagnosis and Treatment. This information is supplemented by reviews of analyst reports, company reports, and medical websites. Sources and references are provided.
The Overactive Bladder Disease and Therapy Review provides an overview of the condition, withprevalence numbers for major countries worldwide, information on diagnosis, and an overview of treatment. Dosing and treatment cost information is provided for various treatment types and for medication. General information on the OAB market, as well as sales of leading drugs and therapies are provided.
General description of the condition
Definition and terminology
Prevalence Table (U.S., UK, France, Germany, Italy, Spain, Japan, Korea, Europe, Worldwide)
V. DOSING AND TREATMENT COSTS
Dosing for commonly prescribed drugs
Costs for commonly prescribed non-generic drugs
VI. MARKET SIZE
Sales information for key pharmaceuticals
A sample for this product is available. Please Login/Register to download this sample.